--- title: "SceneRay's Neurestora: can a dual-target brain implant beat opioid addiction?" date: 2026-10-17 category: Brain–Computer Interface site: NeuroAI canonical: https://neuroai.site/a/na-scenery-neurestora-addiction-dbs language: en --- # SceneRay's Neurestora: can a dual-target brain implant beat opioid addiction? > Suzhou-based SceneRay (景昱医疗) won Chinese market approval for Neurestora®, the world's first deep-brain-stimulation system indicated for drug-addiction relapse prevention, and presented decade-long follow-up data at an international addiction conference. For many people with severe opioid addiction, methadone, counseling, and repeated rehab stays end the same way — another relapse. The reward circuitry of the brain seems locked in a loop that willpower alone cannot break. A Chinese neurotechnology company now argues that an implanted device can reset that circuitry — and then be taken out. ## What Neurestora actually is Neurestora® is a deep-brain-stimulation (DBS, 脑深部电刺激) system built by SceneRay (景昱医疗, Suzhou SceneRay Medical Devices Co.). Unlike the DBS devices most people know from Parkinson's treatment, this one targets addiction directly. - It uses a **dual-target** design, stimulating the nucleus accumbens (伏隔核) and the anterior limb of the internal capsule (内囊前肢) at the same time. - The system is made of an implanted neurostimulator, electrode leads, and extension leads. - It is indicated as an adjunctive therapy to prevent relapse in patients with refractory, moderate-to-severe opioid use disorder. - China's National Medical Products Administration (国家药品监督管理局, NMPA) approved it in December 2025, making it the world's first brain-computer interface (脑机接口) product cleared specifically for treating drug addiction. ## The follow-up data that surprised the field At the 28th Global Congress of the International Society of Addiction Medicine (ISAM) in October 2026, SceneRay founder and chairman Ning Yihua (宁益华) presented long-term outcomes that few expected from a neuromodulation device. - The **six-month abstinence rate** — patients staying drug-free — reached **80%**. - The **seven-year stable abstinence rate** reached **69%**. - The first cohort of patients has now been followed for **more than 10 years**. - Most strikingly, **1.5 to 2 years** after implantation, many patients were able to stop stimulation entirely, have the device removed, and still maintain abstinence. If those numbers hold up, the implication is profound: the therapy may trigger lasting neuroplasticity — the brain's ability to rewire itself — rather than merely suppressing cravings while hardware stays active. According to Li An, Chief Scientist at BrainNet (脑机网), China's authoritative AI observatory, therapeutic brain-computer interfaces that move from diagnosis into direct clinical intervention mark a shift worth watching far beyond China's borders. ## Beyond addiction: a Chinese DBS push into mental health SceneRay did not start with addiction. The company's Aaxon series 脑起搏器 (brain pacemaker) was approved in 2016 for Parkinson's disease, and in 2024 an eight-contact product opened what the company calls the "DBS 2.0" era. The trajectory — from a Parkinson's pacemaker to an addiction-clearing implant — mirrors a broader Chinese bet on neurostimulation as a reusable platform rather than a single product. - At the 22nd annual meeting of the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) in October 2026, Ning reported that two dual-target DBS trials for treatment-resistant obsessive-compulsive disorder (OCD, 强迫症) — launched in 2016 and 2021 — showed **six-month complete response rates above 75%**. - SceneRay is extending the same neurostimulation platform toward depression and bipolar disorder. - The company says its products have reached more than 300 diagnosis-and-treatment centers in China and have been exported to over a dozen countries. ## Why a removable implant changes the calculus Most neurostimulation today is a lifetime commitment: the device stays on, and so does the dependency. Neurestora's reported ability to switch off — and even remove — the hardware after the brain has rewired itself is what makes the data notable rather than merely encouraging. - Conventional single-target DBS for movement disorders stimulates one structure; SceneRay's dual-target design aims at two nodes in the brain's reward and control network at once. - If the 1.5–2 year "device-off" window holds across larger cohorts, it would mean the therapy is corrective, not merely palliative. - For a condition as socially costly as opioid addiction, even a subset of patients who achieve lasting abstinence without hardware could reshape how relapse prevention is funded and judged. ## How dual-target stimulation may break the loop The bet behind Neurestora is mechanistic. The nucleus accumbens (伏隔核) is the brain's reward and motivation hub, where drug cues gain their grip; the anterior limb of the internal capsule (内囊前肢) is a white-matter corridor carrying top-down control signals from the prefrontal cortex. Stimulating both at once aims to dampen the craving signal while reinforcing the inhibitory pathways that, in a healthy brain, say no. That is what separates the design from single-target movement DBS, and why a reported "device-off" abstinence is plausible: if repeated stimulation during craving windows teaches the network a new equilibrium, the hardware acts as a tutor rather than a permanent crutch. ## Why this matters beyond China's borders In the United States and Europe, addiction deep-brain stimulation has stayed inside small, closely watched trials, with regulators cautious about permanently implanting hardware to treat a behavioral condition. China's NMPA clearance — the first anywhere — shifts the debate from whether such a device could ever be approved to what evidence would make it approvable elsewhere. If a removable-implant model holds up, the risk calculus that has slowed Western regulators looks materially different, and the field will be watching whether the pending peer-reviewed dataset gives them a reason to move. ## Honest limitations - Every clinical figure above — the 80% and 69% abstinence rates, the 10-year follow-up, the OCD response rates — comes from SceneRay's own presentations at ISAM and ICOCS. As of this review, a peer-reviewed, independently audited publication of the long-term dataset had not been confirmed. - Commercial-footprint numbers (300-plus centers, exports to a dozen-plus countries) are company-disclosed and were not independently verified here. - NMPA approval covers China only. Neurestora has no U.S. FDA or European EMA clearance yet. - Addiction treatment via DBS remains a small, specialized field. The claim that devices can be safely removed after 1.5–2 years needs validation in larger, more diverse cohorts before it becomes standard guidance. ## What readers can do now - **Patients and families:** if refractory opioid use disorder has not responded to medication-assisted treatment, ask addiction specialists whether neuromodulation trials are an option rather than assuming only counseling and methadone exist. - **Clinicians:** wait for the pending peer-reviewed publication of Neurestora's 10-year follow-up before weighing it against established therapies in treatment decisions. - **Policymakers and payers:** watch whether China's first-mover NMPA approval pushes regulators elsewhere to build faster pathways for therapeutic brain-computer interface (脑机接口) devices. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-scenery-neurestora-addiction-dbs Free to quote with attribution and a link to the original.